Janux Therapeutics
Janux Therapeutics' revenue fell 5.5% to $10 million in fiscal 2025. Its operating margin was −1,576.7%, down from −933.6% a year earlier. Free cash flow was −$83 million. The diluted share count rose 15.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Janux Therapeutics does
Janux Therapeutics is a clinical-stage drug company, which means it tests experimental medicines in people and has none approved for sale. It works on cancer immunotherapies, drugs that guide the body's immune system to attack tumors. Its main approach uses T cell engagers, which link a patient's immune cells to a cancer cell. Janux designs its versions to switch on mainly at the tumor, aiming to limit harm to healthy tissue.
Its first clinical candidate, JANX007, targets a protein called PSMA and is in a Phase 1 trial in men with metastatic castration-resistant prostate cancer. In 2025 it began expansion studies of the drug in specific groups of patients. The second, JANX008, targets a protein called EGFR and is in a Phase 1 trial in several solid tumor types. It also has a third platform, called ARM, aimed at autoimmune diseases as well as cancer. A Phase 1 study of its first ARM drug, JANX011, which targets B cells, has started in healthy volunteers. Its other programs are still in the discovery or preclinical stage.
Janux has no approved products and no revenue from selling drugs. It has lost money since it started and says it may never become profitable. It relies on outside organizations to run its clinical trials.
Its biggest risks, as it describes them
- Net losses since it started, with no assurance it will ever earn revenue or profit.
- Needing more capital, which could mean delaying programs or diluting shareholders.
- Early-stage candidates: only JANX007 and JANX008 are in trials, and early results may not hold up later.
- Novel technology that makes timing, results, cost and regulatory approval hard to predict.
- Relying on outside organizations to run clinical trials, and on key personnel.
Income statement
Janux Therapeutics lost money in fiscal 2025: a net loss of $114 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 375 | 327 | 344 | 1,025 | 967 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 29.5x | 20.1x | 26.8x | 59.2x | 39.0x |
| Quick ratio | 29.5x | 20.1x | 26.8x | 59.2x | 39.0x |
Cash flow
Projections
Project Janux Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Janux Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −654.7% | −386.2% | −838.3% |
| Altman Z'' | 13.09 | 32.65 | 26.48 |
| Accruals ratio | −2.1% | −3.5% | −3.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Janux Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 0 | 4 | 9 | 8 | 11 | 10 |
| Revenue growth | — | — | 136.8% | −6.1% | 31.0% | −5.5% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 3 | 26 | 53 | 55 | 68 | 126 |
| Operating income | −5 | −33 | −67 | −73 | −99 | −158 |
| Net income | −7 | −33 | −63 | −58 | −69 | −114 |
| Diluted EPS (US$) | −7.41 | −1.39 | −1.52 | −1.32 | −1.28 | −1.83 |
| Diluted shares (millions) | 1 | 24 | 42 | 44 | 54 | 62 |
| Cash flow | ||||||
| Cash from operations | −4 | −17 | −43 | −51 | −44 | −82 |
| Capital expenditure | 0 | 2 | 6 | 2 | 0 | 1 |
| Free cash flow | −4 | −18 | −49 | −52 | −44 | −83 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 7 | 17 | 20 | 33 | 40 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 8 | 375 | 327 | 344 | 1,025 | 967 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 16 | 380 | 364 | 380 | 1,062 | 1,002 |
| Total liabilities | 9 | 14 | 43 | 36 | 39 | 45 |
| Shareholders' equity | −15 | 366 | 321 | 344 | 1,023 | 957 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | −905.4% | −779.0% | −902.9% | −933.6% | −1,576.7% |
| Net margin | — | −898.3% | −732.2% | −721.2% | −651.6% | −1,136.2% |
| Free cash flow margin | — | −507.5% | −573.2% | −648.6% | −417.2% | −832.8% |
| Rule of 40 (growth + FCF margin) | — | — | −436.4% | −654.7% | −386.2% | −838.3% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −18.6% | −18.4% | −17.5% | −10.1% | −11.5% |
| Return on assets | — | −16.5% | −17.0% | −15.7% | −9.6% | −11.0% |
| Net debt to EBITDA | — | — | — | — | — | — |